Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STOK 
Stoke Therapeutics Inc (STOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: STOK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $24.22
1 Year Target Price $24.22
| 7 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.43% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.08B USD | Price to earnings Ratio 22.71 | 1Y Target Price 24.22 |
Price to earnings Ratio 22.71 | 1Y Target Price 24.22 | ||
Volume (30-day avg) 10 | Beta 1.15 | 52 Weeks Range 5.35 - 20.00 | Updated Date 08/29/2025 |
52 Weeks Range 5.35 - 20.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.5 | Actual -0.4 |
Profitability
Profit Margin 26.26% | Operating Margin (TTM) -197.58% |
Management Effectiveness
Return on Assets (TTM) 7.27% | Return on Equity (TTM) 18.17% |
Valuation
Trailing PE 22.71 | Forward PE 208.33 | Enterprise Value 837384979 | Price to Sales(TTM) 5.42 |
Enterprise Value 837384979 | Price to Sales(TTM) 5.42 | ||
Enterprise Value to Revenue 4.19 | Enterprise Value to EBITDA 19.81 | Shares Outstanding 54797400 | Shares Floating 38107768 |
Shares Outstanding 54797400 | Shares Floating 38107768 | ||
Percent Insiders 4.58 | Percent Institutions 118.18 |
Upturn AI SWOT
Stoke Therapeutics Inc
Company Overview
History and Background
Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts. It is a biotechnology company focused on developing treatments for genetic diseases by precisely upregulating protein expression. It utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to target the underlying cause of genetic diseases.
Core Business Areas
- RNA-Based Therapies: Stoke focuses on developing antisense oligonucleotides (ASOs) that selectively increase protein production from a healthy copy of a gene to treat diseases caused by haploinsufficiency.
- TANGO Platform: The company's TANGO platform is used to identify and develop ASOs that can selectively increase protein production. This platform is the core of their research and development efforts.
Leadership and Structure
The leadership team includes Edward M. Kaye, M.D. (CEO), Barry Ticho, M.D., Ph.D. (Chief Medical Officer), and other executives in research, development, and finance. The company operates with a focus on research and clinical development, structured around its TANGO platform.
Top Products and Market Share
Key Offerings
- STK-001 ( Dravet Syndrome ): STK-001 is Stoke's lead product candidate for the treatment of Dravet syndrome, a severe form of epilepsy. It is designed to upregulate the expression of the SCN1A gene. The market for Dravet syndrome treatments is relatively small but growing, with competitors including Jazz Pharmaceuticals (Epidiolex) and Zogenix (Fintepla). Stoke does not have any approved products, so it has no market share.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high levels of research and development, significant regulatory hurdles, and potential for high rewards for successful products. There is a strong focus on developing novel therapies for genetic diseases.
Positioning
Stoke Therapeutics is positioned as a leader in RNA-based therapies targeting the underlying cause of genetic diseases. Its TANGO platform provides a competitive advantage in identifying and developing novel ASOs to selectively increase protein production.
Total Addressable Market (TAM)
The TAM for genetic disease therapies is substantial and growing, driven by advances in genomics and RNA-based therapeutics. The total market is estimated to be in the tens of billions. Stoke's positioning with STK-001 targeting Dravet syndrome aims at a smaller segment within this broader market, providing potential for future expansion to other genetic diseases.
Upturn SWOT Analysis
Strengths
- Proprietary TANGO platform
- Focus on RNA-based therapies
- Experienced leadership team
- Lead product candidate in clinical development (STK-001)
Weaknesses
- No currently approved products
- Reliance on a single lead product candidate
- High research and development costs
- Cash Burn
Opportunities
- Expansion of TANGO platform to other genetic diseases
- Potential for partnerships and collaborations
- Advancements in RNA-based therapeutics
- Positive clinical trial results for STK-001
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other biotechnology companies
- Patent disputes
- Funding risks
Competitors and Market Share
Key Competitors
- JAZZ
- ZYNE
Competitive Landscape
Stoke competes with companies developing treatments for genetic diseases, particularly those targeting epilepsy. Its TANGO platform provides a competitive advantage in developing novel RNA-based therapies. Competitors focusing on Dravet syndrome include Jazz Pharmaceuticals (Epidiolex) and Zogenix (Fintepla).
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by preclinical progress and the advancement of STK-001 through clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of STK-001 and other pipeline products. Analyst estimates vary, with projections based on clinical trial success and market potential.
Recent Initiatives: Recent initiatives include progressing STK-001 through clinical trials, expanding the pipeline of product candidates, and securing additional funding.
Summary
Stoke Therapeutics is a clinical-stage biotech company with promising RNA-based therapeutics. Its TANGO platform offers a competitive edge, but it faces the challenges of clinical trial risks and regulatory hurdles. Successful development and commercialization of STK-001 are critical for its long-term success. Funding remains a constant concern for the company as clinical trials progress. The company needs to be aware of potential competitors who may come out with similar therapeutics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Stoke Therapeutics Inc. Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is approximate and may vary based on source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stoke Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2019-06-19 | Interim CEO & Director Mr. Ian F. Smith A.C.A., C.P.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | |
Full time employees 128 | |||
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.